Announcement Details

View all announcements

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc

(the “Company”)

 

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company’s Financial Controller and Company Secretary (PDMR), and his wife, Olena Wright, have purchased a total of 434,704 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) at an average price of 5.76p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,532,109 Ordinary Shares, representing approximately 0.35 per cent of the Company’s issued share capital.

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1. Details of PDMR/person closely associated with them
a) Name Andrew Wright
b) Position/status PDMR: Financial Controller and Company Secretary
c) Initial notification/
amendment
Initial notification
2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument Ordinary shares of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24
b) Nature of the transaction Standalone acquisition of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
GBP £0.056799 90,554
d) Aggregated information
–       Aggregated volume
–       Price
Price(s) Volume(s)
GBP £5,132.38 90,554
e) Date of the transaction 2020-06-29
f) Place of the transaction London Stock Exchange
XLON

 

1. Details of PDMR/person closely associated with them
a) Name Olena Wright
b) Position/status PCA: Spouse of Andrew Wright (PDMR: Financial Controller and Company Secretary)
c) Initial notification/
amendment
Initial notification
2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument Ordinary shares of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24
b) Nature of the transaction Standalone acquisition of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
GBP £0.057799 344,150
d) Aggregated information
–       Aggregated volume
–       Price
Price(s) Volume(s)
GBP £19,891.53 344,150
e) Date of the transaction 2020-06-29
f) Place of the transaction London Stock Exchange
XLON

 

Enquiries:

Hemogenyx Pharmaceuticals plc hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
View all announcements